Langues

23 October 2019 - Neurolixis' Parkinson's disease project showcased by French regional business accelerator

Neurolixis' development of NLX-112, a drug candidate for treatment of dyskinesia in Parkinson's disease and other movement disorders, was showcased by the Castres-Mazamet Technopole, a French regional entrepreneur accelerator in a video interview and article. In particular, these highlighted the recent financial support received by Neurolixis from the US Dept of Defense. The accelerator assists the French branch of Neurolixis in fundraising, recruitment and business networking.

See the full article here.